Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOL2506 Safety Extension Study in HR+, HER2-Negative Breast Cancer (OVELIA Extension)
NCT05645536Phase 3Enrolling by invitation
- Sponsor
- Tolmar
- Start
- Dec 2022
- Primary completion
- Mar 2030
- Modality
- Peptides, Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of leuprolide acetate in breast cancer, sponsored by Tolmar. Started Dec 2022; status: enrolling by invitation.
02
Drugs
leuprolide acetate
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05645536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05645536.